Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …

Background The safety and effectiveness of reduced-dose apixaban 2.5 mg twice daily (BID)
have not been elucidated thoroughly in Japanese patients with nonvalvular atrial fibrillation …

Background: The risk of bleeding and stroke/systemic embolism (SE) events associated with
apixaban vs. warfarin among oral anticoagulant-naïve Japanese patients with non-valvular …

Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …

Introduction Apixaban has been shown to be superior to warfarin in patients with non-
valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in …

Aims To compare the effectiveness and safety of off-label underdosed apixaban with on-
label standard dose apixaban in Asian patients with atrial fibrillation (AF). Methods and …

Background: Guidelines recommend warfarin as the standard of care for patients with atrial
fibrillation (AF) at moderate or high risk for stroke. This phase II study assessed the effects of …

East Asians are reportedly at high risk of anticoagulant-related bleeding; therefore, some
physicians prefer to prescribe low-dose direct oral anticoagulants (DOACs). Little is known …

Background A global, randomized clinical trial indicated the efficacy and safety of apixaban
in stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). However, data in …

Aims Real-world data on treatment persistence, safety and effectiveness of non-Vitamin K
antagonist oral anticoagulants (NOACs) play an important role in the assessment of risks …